Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia is characterized by clonal proliferation and progressive accumulation of B-cell lymphocytes that typically express CD19, CD5 and CD23. The lymphocytes usually infiltrate the bone marrow, peripheral blood, lymph nodes, and spleen. The diagnosis is established by immunophenotyping circulating B-lymphocytes, and prognosis is defined by two staging systems (Rai and Binet) established by physical examination and blood counts, as well as by several biological and genetic markers. In this update, we present the recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia for the diagnosis and treatment of chronic lymphocytic leukemia. The following recommendations are based on an extensive literature review with the aim of contributing to more uniform patient care in Brazil and possibly in other countries with a similar social-economic profile.

Citing Articles

Evaluation of Diagnostic Usefulness of CD200 Expression in B-cell Chronic Lymphoproliferative Disorders.

Purohit A, Satiza M, Somasundaram V, Sharma R, Mishra P, Seth T Indian J Hematol Blood Transfus. 2023; 39(4):684-690.

PMID: 37786819 PMC: 10542070. DOI: 10.1007/s12288-022-01622-1.

Expert consensus on the management of chronic lymphocytic leukaemia in Asia.

Tse E, Kwong Y, Goh Y, Bee P, Ng S, Tan D Clin Exp Med. 2023; 23(6):2895-2907.

PMID: 36795237 PMC: 10543526. DOI: 10.1007/s10238-023-01007-2.

Role of Sirtuins in the Pathobiology of Onco-Hematological Diseases: A PROSPERO-Registered Study and In Silico Analysis.

Goes J, Carvalho L, Germano de Oliveira R, de Lima Melo M, Novaes L, Moreno D Cancers (Basel). 2022; 14(19).

PMID: 36230534 PMC: 9561980. DOI: 10.3390/cancers14194611.

Lower access to risk stratification tests and drugs, and worse survival of chronic lymphocytic leukaemia patients treated in public as compared to private hospitals in Brazil: A retrospective analysis of the Brazilian registry of chronic lymphocytic....

Pfister V, Marques F, Parra F, Yamamoto M, Vescovi Goncalves M, Perobelli L EJHaem. 2022; 3(3):698-706.

PMID: 36051063 PMC: 9422035. DOI: 10.1002/jha2.444.

Prognostic value of CD20 antigen mediated immune checkpoint inhibition in patients with acute or chronic lymphocytic leukemia: A protocol for systematic review.

Mkhwanazi Z, Mfusi S, Nkambule B Medicine (Baltimore). 2022; 101(7):e28868.

PMID: 35363193 PMC: 9282114. DOI: 10.1097/MD.0000000000028868.

References

OBrien S, Lamanna N, Kipps T, Flinn I, Zelenetz A, Burger J . A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015; 126(25):2686-94. PMC: 4732760. DOI: 10.1182/blood-2015-03-630947. View

Teeling J, Mackus W, Wiegman L, van den Brakel J, Beers S, French R . The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006; 177(1):362-71. DOI: 10.4049/jimmunol.177.1.362. View

Burger J, Keating M, Wierda W, Hartmann E, Hoellenriegel J, Rosin N . Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014; 15(10):1090-9. PMC: 4174348. DOI: 10.1016/S1470-2045(14)70335-3. View

Hallek M . Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015; 90(5):446-60. DOI: 10.1002/ajh.23979. View

Toze C, Dalal C, Nevill T, Gillan T, Abou Mourad Y, Barnett M . Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort. Br J Haematol. 2012; 158(2):174-185. DOI: 10.1111/j.1365-2141.2012.09170.x. View

Roberts A, Davids M, Pagel J, Kahl B, Puvvada S, Gerecitano J . Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 374(4):311-22. PMC: 7107002. DOI: 10.1056/NEJMoa1513257. View

Lozanski G, Heerema N, Flinn I, Smith L, Harbison J, Webb J . Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004; 103(9):3278-81. DOI: 10.1182/blood-2003-10-3729. View

Tam C, OBrien S, Wierda W, Kantarjian H, Wen S, Do K . Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008; 112(4):975-80. PMC: 3952498. DOI: 10.1182/blood-2008-02-140582. View

Rawstron A, Bottcher S, Letestu R, Villamor N, Fazi C, Kartsios H . Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia. 2012; 27(1):142-9. DOI: 10.1038/leu.2012.216. View

10.

Yamamoto J, Goodman M . Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control. 2007; 19(4):379-90. DOI: 10.1007/s10552-007-9097-2. View

11.

Robak T . Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia. Hematology. 2005; 9(5-6):387-400. DOI: 10.1080/10245330400018599. View

12.

Zenz T, Krober A, Scherer K, Habe S, Buhler A, Benner A . Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood. 2008; 112(8):3322-9. DOI: 10.1182/blood-2008-04-154070. View

13.

Zenz T, Eichhorst B, Busch R, Denzel T, Habe S, Winkler D . TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010; 28(29):4473-9. DOI: 10.1200/JCO.2009.27.8762. View

14.

Van Dyke D, Werner L, Rassenti L, Neuberg D, Ghia E, Heerema N . The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience. Br J Haematol. 2016; 173(1):105-13. PMC: 4963001. DOI: 10.1111/bjh.13933. View

15.

Sher T, Miller K, Lawrence D, Whitworth A, Hernandez-Ilizaliturri F, Czuczman M . Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma. 2010; 51(1):85-8. DOI: 10.3109/10428190903406806. View

16.

Rawstron A, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J . A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2015; 30(4):929-36. PMC: 4832072. DOI: 10.1038/leu.2015.313. View

17.

Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que T . The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994; 8(10):1640-5. View

18.

Swerdlow S, Campo E, Pileri S, Lee Harris N, Stein H, Siebert R . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375-90. PMC: 4874220. DOI: 10.1182/blood-2016-01-643569. View

19.

OBrien S, Kantarjian H, Thomas D, Cortes J, Giles F, Wierda W . Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003; 98(12):2657-63. DOI: 10.1002/cncr.11871. View

20.

Catovsky D, Richards S, Matutes E, Oscier D, Dyer M, Bezares R . Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007; 370(9583):230-239. DOI: 10.1016/S0140-6736(07)61125-8. View